Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prelude Therapeutics Inc

0.7550
+0.01502.03%
Post-market: 0.76500.0100+1.32%19:41 EST
Volume:86.43K
Turnover:64.83K
Market Cap:41.55M
PE:-0.43
High:0.7680
Open:0.7500
Low:0.7020
Close:0.7400
Loading ...

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

GlobeNewswire
·
09 Oct 2024

Prelude Therapeutics Raised to Buy From Neutral by HC Wainwright & Co.

Dow Jones
·
19 Sep 2024

Prelude Therapeutics Inc : H.c. Wainwright Raises to Buy From Neutral

THOMSON REUTERS
·
19 Sep 2024

HC Wainwright Upgrades Prelude Therapeutics to Buy From Neutral

MT Newswires Live
·
19 Sep 2024

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Simply Wall St.
·
16 Sep 2024

Prelude Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Sep 2024

Hold Rating on Prelude Therapeutics Amid Cautious Optimism for PRT3789’s Early Promise

TIPRANKS
·
16 Sep 2024

Prelude Therapeutics (PRLD) Gets a Sell from Barclays

TIPRANKS
·
16 Sep 2024

Buy Rating Affirmed for Prelude Therapeutics on Promising PRT3789 Trial Results and Strong Financial Position

TIPRANKS
·
16 Sep 2024

Prelude Therapeutics: Uncertainties in Drug Efficacy and Dosing Prompt Sell Rating

TIPRANKS
·
14 Sep 2024

BRIEF-Prelude Therapeutics Says PRT3789 Generally Well-Tolerated With No Dose-Limiting Toxicities

Reuters
·
13 Sep 2024

Prelude Therapeutics Says PRT3789 Shows 'Encouraging Signs' in Phase 1 Trial; Shares Fall

MT Newswires Live
·
13 Sep 2024

Prelude Therapeutics Says PRT3789 Shows 'Encouraging Signs' in Phase 1 Trial; Shares Fall

MT Newswires Live
·
13 Sep 2024

Prelude Therapeutics Inc - PRT3789 Generally Well-Tolerated With No Dose-Limiting Toxicities

THOMSON REUTERS
·
13 Sep 2024

Prelude Therapeutics’ Smarca2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

THOMSON REUTERS
·
13 Sep 2024

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

GlobeNewswire
·
13 Sep 2024